BBI-940 IND in metastatic breast cancer accepted; POTENTIATE trial discontinued
“The acceptance of the BBI-940 IND marks an important milestone for our first-in-class Kinesin oral degrader program, enabling us to advance this differentiated anti-cancer approach into clinical development,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “In parallel, our portfolio prioritization and disciplined capital allocation sharpen our focus on BBI-940, maximizing our potential to deliver high-impact therapies for patients with high unmet need cancers.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.